Votrient 200 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DB25FC7P4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,478
Award facts
- Contract value 100% obligated
- $11,477.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,477.96 to AmerisourceBergen Drug Corp for the supply of Votrient (pazopanib) 200 mg tablets in a quantity of 120 units. This award, issued on June 6, 2025, with an ultimate completion date of June 30, 2025, represents a firm fixed-price contract with no set-aside designation. The contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs.
This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. Votrient, a tyrosine kinase inhibitor used primarily in oncology treatment, represents one of the specialized medications within the company's extensive portfolio of brand-name and generic drugs, vaccines, and medical supplies. The firm fixed-price structure and relatively modest ceiling value reflect the standardized procurement methodology employed across the DLA's pharmaceutical supply chain operations supporting Defense Health Agency and other federal healthcare customers.
Quick answers
Who was awarded contract SPE2DB25FC7P4?
SPE2DB25FC7P4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on June 6, 2025.
How much is contract SPE2DB25FC7P4 worth?
The government has obligated $11,478 on SPE2DB25FC7P4.
Is contract SPE2DB25FC7P4 an order under another contract?
Yes. SPE2DB25FC7P4 is a delivery order under SPE2DB20D1100, an indefinite delivery contract.
Was contract SPE2DB25FC7P4 competed?
The extent of competition for SPE2DB25FC7P4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award